NCT02029001 2025-08-07
MOST plus
Centre Leon Berard
Phase 2 Recruiting
Clinical Trials
14 trialsNCT05467189 2022-07-20
Antineoplastic Drugs in Elderly Patients
Shandong University
Recruiting
NCT01636908 2021-04-15
ICK
Amsterdam UMC, location VUmc
Phase NA Completed
NCT01190241 2020-11-20
TSAP
Amsterdam UMC, location VUmc
Phase NA Terminated
NCT00968968 2019-06-10
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
Novartis
Phase 3 Terminated
NCT02142036 2019-03-13
MetAction
Oslo University Hospital
Phase 2 Completed
NCT01290354 2017-11-13
Exploratory Lapatinib (Positron Emission Tomography) PET Study in Subjects With Breast Cancer
GlaxoSmithKline
Phase 1 Completed
NCT01332396 2017-04-26
Drug Use Investigation for TYKERB Tablet (All Case Investigation)
Novartis
Completed
NCT01328054 2016-06-08
A Study in Cancer Patients to Evaluate the Effect of Lapatinib on the QTc Interval
GlaxoSmithKline
Phase 4 Completed
NCT01087983 2015-11-11
Lapatinib With Sirolimus or Metformin
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01427322 2015-07-08
Randomized RT +/- Lapatinib for Advanced Solid Tumor Cancer Patients Receiving Radiation Therapy for Metastatic Disease
Virginia Commonwealth University
Phase EARLY_PHASE1 Terminated
NCT01666431 2014-12-03
Single-center Investigator Initiated Pilot Study Investigating the Tumor Response of Squamous Cell Carcinoma Lesions in Patients Under Lapatinib Treatment
University of Zurich
Phase 2 Terminated
NCT00975988 2014-10-27
Regulatory TYKERB® Tablets PMS
GlaxoSmithKline
Completed
NCT00259987 2009-05-18
Effects Of Lapatinib (GW572016) In Patients With Relapsed Adenocarcinoma Of The Esophagus
GlaxoSmithKline
Phase 2 Completed